866-997-4948(US-Canada Toll Free)

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-API Insights, 2015

Published By :

DelveInsight

Published Date : Apr 2015

Category :

Cancer

No. of Pages : N/A

Summary

DelveInsights, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-API Insights, 2015,report provides Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. The Report provides the India and China API Manufactures who are driving the current API Market. DelveInsights report also highlights the patent, patent exclusivity information and competitive landscape. The research analysis also presents the global sales forecasts data for the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer drugs till 2016.
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.
India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China.
Data Sources
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
Indication Overview
Marketed Drugs Assessment
Marketed Details of Drugs by Application Type
Marketed Details of Drugs (NDA) by Marketing Status
Marketed Details of Drugs by Patent Expiration Timeline
The Active Pharmaceutical Ingredient (API) Manufacturers Assessment
The API Manufacturers by the United States Drug Master File (US DMF) Status
The API Manufacturers by the US DMF Status (Drug Specific)
Drugs Market Data and Forecasted Sales Figures (2012-2016)
Marketed Drugs Information
Drugs Description
Global Active Pharmaceutical Manufacturers
Approval Status
Patent and Exclusivity Details
Company Overview
Discontinued Drugs Information

List of Table

List of Tables
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, Marketed Drugs by Application Type, 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status, 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, (Year), 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, API Manufacturers by US DMF Status, 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, Global Sales (in million USD), 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, API Manufacturers, Global, 2015
Discontinued Drugs for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, 2015

List of Chart

List of Figures
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, Marketed Drugs by Application Type (%), 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, (Year), 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, API Manufacturers by US DMF Status (%), 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, Global Sales (in million USD), 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, Patent/Exclusivity Expiry (Year), 2015

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *